[ { "report_key": "2026:q1", "period_label": "2026 Q1", "date": "2026-05-07", "title": "Kvartalsrapport Q1 2026", "original_title": "Active Biotech Delårsrapport Q1 2026", "category": "Interimsrapport", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://view.news.eu.nasdaq.com/view?id=bee48b273a4f615b8fb942a861d58aa1a&lang=sv&src=listed", "language": "sv", "report_type": "interim-report", "fiscal_year": 2026, "quarter": "q1", "documents": [ { "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2026", "title": "Kvartalsrapport Q1 2026", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/aa9154e51b3d97e5e453283ca69f7982a", "date": "2026-05-07", "period": "2026-q1", "form_type": "interim-report", "report_key": "2026:q1", "filename": "Active_Biotech_Rapport_2026_Q1_Sve.pdf", "text_chars": 49140, "sha256": "e250c958f1f47dd069c5af84cd6f79ff434a8dd18adfbe6d65b227a9ad69c337", "url": "/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q1-2026", "absolute_url": "https://spela.port0.org/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q1-2026", "txt_url": "/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt", "parts": [ { "number": 1, "url": "/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q1-2026/part-001.html", "chars": 49140 } ] } ], "alternatives": [] }, { "report_key": "2025:annual", "period_label": "2025 Årsredovisning", "date": "2026-04-01", "title": "Årsredovisning 2025", "original_title": "Årsredovisning 2025 Active Biotech AB (publ)", "category": "Bokslut och Verksamhetsberättelse", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://view.news.eu.nasdaq.com/view?id=bc60641b2a257ed8ab19c1b17b5ec5efc&lang=sv&src=listed", "language": "sv", "report_type": "annual-report", "fiscal_year": 2025, "quarter": "annual", "documents": [ { "doc_id": "nasdaq-nordic-arsredovisning-2025", "title": "Årsredovisning 2025", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/a021c93eb2bff7249e5f5fdf0518a9c4b", "date": "2026-04-01", "period": "2025-annual", "form_type": "annual-report", "report_key": "2025:annual", "filename": "Active_Biotech_2025_Sve.pdf", "text_chars": 283895, "sha256": "88bf9db8a8abec5d77d1333dc40e9fc0c94fa3a357c6501b67d9985bc8247a9b", "url": "/company/active-biotech/documents/nasdaq-nordic-arsredovisning-2025", "absolute_url": "https://spela.port0.org/company/active-biotech/documents/nasdaq-nordic-arsredovisning-2025", "txt_url": "/company/active-biotech/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/active-biotech/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt", "parts": [ { "number": 1, "url": "/company/active-biotech/documents/nasdaq-nordic-arsredovisning-2025/part-001.html", "chars": 179320 }, { "number": 2, "url": "/company/active-biotech/documents/nasdaq-nordic-arsredovisning-2025/part-002.html", "chars": 104573 } ] } ], "alternatives": [] }, { "report_key": "2025:q4", "period_label": "2025 Q4", "date": "2026-02-12", "title": "Kvartalsrapport Q4 2025", "original_title": "Active Biotech Bokslutsrapport 2025", "category": "Bokslutskommuniké", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://view.news.eu.nasdaq.com/view?id=b05fe5be301b2d2469e148da1273a9c7b&lang=sv&src=listed", "language": "sv", "report_type": "year-end-report", "fiscal_year": 2025, "quarter": "q4", "documents": [ { "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2025", "title": "Kvartalsrapport Q4 2025", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/aca159b19464ce4a453db1195556593e8", "date": "2026-02-12", "period": "2025-q4", "form_type": "year-end-report", "report_key": "2025:q4", "filename": "Active_Biotech_Rapport_2025_Q4_Sve.pdf", "text_chars": 54948, "sha256": "51d53e436a17b0f7117d184eeec2af8688c0ff7fe40da65c08c7e7435c05d449", "url": "/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q4-2025", "absolute_url": "https://spela.port0.org/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q4-2025", "txt_url": "/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt", "parts": [ { "number": 1, "url": "/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q4-2025/part-001.html", "chars": 54948 } ] } ], "alternatives": [] }, { "report_key": "2025:q3", "period_label": "2025 Q3", "date": "2025-11-06", "title": "Kvartalsrapport Q3 2025", "original_title": "Active Biotech delårsrapport Q3 2025", "category": "Interimsrapport", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://view.news.eu.nasdaq.com/view?id=b5322e87a44419553cc1746c567ae2fd0&lang=sv&src=listed", "language": "sv", "report_type": "interim-report", "fiscal_year": 2025, "quarter": "q3", "documents": [ { "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2025", "title": "Kvartalsrapport Q3 2025", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/a72cf8adad377196c5f57d9153e93fe7b", "date": "2025-11-06", "period": "2025-q3", "form_type": "interim-report", "report_key": "2025:q3", "filename": "Active_Biotech_Rapport_2025_Q3_Sve.pdf", "text_chars": 62633, "sha256": "d1480f822f3ddd272476ed46d0c6a45cb5ba32c625da8685b3ca91513738d4a4", "url": "/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q3-2025", "absolute_url": "https://spela.port0.org/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q3-2025", "txt_url": "/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt", "parts": [ { "number": 1, "url": "/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q3-2025/part-001.html", "chars": 62633 } ] } ], "alternatives": [] }, { "report_key": "2025:q2", "period_label": "2025 Q2", "date": "2025-08-21", "title": "Kvartalsrapport Q2 2025", "original_title": "DELÅRSRAPPORT Q2 2025", "category": "Halvårsrapport", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://view.news.eu.nasdaq.com/view?id=b7e1ca8a151719b1e37058ff128147e77&lang=sv&src=listed", "language": "sv", "report_type": "interim-report", "fiscal_year": 2025, "quarter": "q2", "documents": [ { "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2025", "title": "Kvartalsrapport Q2 2025", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/a2eccc638698c9f2aea2022c142042bb7", "date": "2025-08-21", "period": "2025-q2", "form_type": "interim-report", "report_key": "2025:q2", "filename": "Active_Biotech_Rapport_2025_Q2_Sve.pdf", "text_chars": 58751, "sha256": "85660e7863f0fe0d042a855e88c9e3f23ad15b38847790e7a9faeee8a7ee3425", "url": "/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q2-2025", "absolute_url": "https://spela.port0.org/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q2-2025", "txt_url": "/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt", "parts": [ { "number": 1, "url": "/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q2-2025/part-001.html", "chars": 58751 } ] } ], "alternatives": [] }, { "report_key": "2025:q1", "period_label": "2025 Q1", "date": "2025-05-08", "title": "Kvartalsrapport Q1 2025", "original_title": "Active Biotech delårsrapport Q1 2025", "category": "Interimsrapport", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://view.news.eu.nasdaq.com/view?id=b055430f65efaa49c622e229c9385e108&lang=sv&src=listed", "language": "sv", "report_type": "interim-report", "fiscal_year": 2025, "quarter": "q1", "documents": [ { "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2025", "title": "Kvartalsrapport Q1 2025", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/aecd93218278374230f26f6f12d3c90ea", "date": "2025-05-08", "period": "2025-q1", "form_type": "interim-report", "report_key": "2025:q1", "filename": "Active_Biotech_Rapport_2025_Q1_Sve.pdf", "text_chars": 57126, "sha256": "2a217ea547a4d70cd9d87ff1aa88f1542037927c5188e4337bea8524a4c46526", "url": "/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q1-2025", "absolute_url": "https://spela.port0.org/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q1-2025", "txt_url": "/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt", "parts": [ { "number": 1, "url": "/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q1-2025/part-001.html", "chars": 57126 } ] } ], "alternatives": [] }, { "report_key": "2024:annual", "period_label": "2024 Årsredovisning", "date": "2025-04-07", "title": "Årsredovisning 2024", "original_title": "Årsredovisning 2024 Active Biotech AB (publ)", "category": "Bokslut och Verksamhetsberättelse", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://view.news.eu.nasdaq.com/view?id=b724053a13819d17ec1c9048701f12842&lang=sv&src=listed", "language": "sv", "report_type": "annual-report", "fiscal_year": 2024, "quarter": "annual", "documents": [ { "doc_id": "nasdaq-nordic-arsredovisning-2024", "title": "Årsredovisning 2024", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/ab29fe1da63c9680f3d6aad7159c9a6da", "date": "2025-04-07", "period": "2024-annual", "form_type": "annual-report", "report_key": "2024:annual", "filename": "Active_Biotech_2024_Sve.pdf", "text_chars": 307165, "sha256": "97a68ebdc4b298c49c560a2d6c993da29fdb93c16e92d9b0b3b6789ccc1e917e", "url": "/company/active-biotech/documents/nasdaq-nordic-arsredovisning-2024", "absolute_url": "https://spela.port0.org/company/active-biotech/documents/nasdaq-nordic-arsredovisning-2024", "txt_url": "/company/active-biotech/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/active-biotech/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt", "parts": [ { "number": 1, "url": "/company/active-biotech/documents/nasdaq-nordic-arsredovisning-2024/part-001.html", "chars": 179118 }, { "number": 2, "url": "/company/active-biotech/documents/nasdaq-nordic-arsredovisning-2024/part-002.html", "chars": 128045 } ] } ], "alternatives": [] }, { "report_key": "2024:q4", "period_label": "2024 Q4", "date": "2025-02-13", "title": "Kvartalsrapport Q4 2024", "original_title": "Active Biotech Bokslutsrapport 2024", "category": "Bokslutskommuniké", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://view.news.eu.nasdaq.com/view?id=ba5d12534fe6e12b43c25214f5fba7086&lang=sv&src=listed", "language": "sv", "report_type": "year-end-report", "fiscal_year": 2024, "quarter": "q4", "documents": [ { "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2024", "title": "Kvartalsrapport Q4 2024", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/a3ec16aacb121a02bfd3f46ba313c9765", "date": "2025-02-13", "period": "2024-q4", "form_type": "year-end-report", "report_key": "2024:q4", "filename": "Active_Biotech_Rapport_2024_Q4_Sve.pdf", "text_chars": 62464, "sha256": "1d489c064de78126550f227dfaa46219d75dcc06c14bea92c16e7282d4d53600", "url": "/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q4-2024", "absolute_url": "https://spela.port0.org/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q4-2024", "txt_url": "/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt", "parts": [ { "number": 1, "url": "/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q4-2024/part-001.html", "chars": 62464 } ] } ], "alternatives": [] }, { "report_key": "2024:q3", "period_label": "2024 Q3", "date": "2024-10-21", "title": "Kvartalsrapport Q3 2024", "original_title": "Active Biotech Delårsrapport Q3 2024", "category": "Interimsrapport", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://view.news.eu.nasdaq.com/view?id=bd007a591d56967abc41a0e1a5dbafd77&lang=sv&src=listed", "language": "sv", "report_type": "interim-report", "fiscal_year": 2024, "quarter": "q3", "documents": [ { "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2024", "title": "Kvartalsrapport Q3 2024", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/a4bc6d31be9beb9745e1e34b0e4a1edc4", "date": "2024-10-21", "period": "2024-q3", "form_type": "interim-report", "report_key": "2024:q3", "filename": "AB_Rapport_2024_Q3_Sv.pdf", "text_chars": 63888, "sha256": "77a80580a0321f6c96d9a9f0e4c774c403e922a97bb83990046a2a7ec0f28e58", "url": "/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q3-2024", "absolute_url": "https://spela.port0.org/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q3-2024", "txt_url": "/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt", "parts": [ { "number": 1, "url": "/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q3-2024/part-001.html", "chars": 63888 } ] } ], "alternatives": [] }, { "report_key": "2024:q2", "period_label": "2024 Q2", "date": "2024-08-22", "title": "Kvartalsrapport Q2 2024", "original_title": "Active Biotech delårsrapport Q2 2024", "category": "Halvårsrapport", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://view.news.eu.nasdaq.com/view?id=b3fe2cf10af9bff7a22824dc89c4c966c&lang=sv&src=listed", "language": "sv", "report_type": "interim-report", "fiscal_year": 2024, "quarter": "q2", "documents": [ { "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2024", "title": "Kvartalsrapport Q2 2024", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/ac3cca813fd679370e9c4112973da021a", "date": "2024-08-22", "period": "2024-q2", "form_type": "interim-report", "report_key": "2024:q2", "filename": "AB_Rapport_2024_Q2_Sv.pdf", "text_chars": 55542, "sha256": "f362dcc495266d00e8080a3417b90aacf73918d44a5706df3b43740adc2c07da", "url": "/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q2-2024", "absolute_url": "https://spela.port0.org/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q2-2024", "txt_url": "/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt", "parts": [ { "number": 1, "url": "/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q2-2024/part-001.html", "chars": 55542 } ] } ], "alternatives": [] }, { "report_key": "2024:q1", "period_label": "2024 Q1", "date": "2024-05-08", "title": "Kvartalsrapport Q1 2024", "original_title": "Active Biotech delårsrapport Q1 2024", "category": "Interimsrapport", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://view.news.eu.nasdaq.com/view?id=b95302693ae6c1569f65cf4eb490aeb94&lang=sv&src=listed", "language": "sv", "report_type": "interim-report", "fiscal_year": 2024, "quarter": "q1", "documents": [ { "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2024", "title": "Kvartalsrapport Q1 2024", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/a17370e61d30ce886f91e99fb458bf4a7", "date": "2024-05-08", "period": "2024-q1", "form_type": "interim-report", "report_key": "2024:q1", "filename": "AB_Rapport_2024_Q1_Sv.pdf", "text_chars": 59047, "sha256": "84816ad79acd600c1002df056671c601cd5f3a9014bfa8a375e6691dfc05cd20", "url": "/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q1-2024", "absolute_url": "https://spela.port0.org/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q1-2024", "txt_url": "/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q1-2024/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q1-2024/fulltext.txt", "parts": [ { "number": 1, "url": "/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q1-2024/part-001.html", "chars": 59047 } ] } ], "alternatives": [] }, { "report_key": "2023:annual", "period_label": "2023 Årsredovisning", "date": "2024-04-22", "title": "Årsredovisning 2023", "original_title": "Årsredovisning 2023 Active Biotech AB (publ)", "category": "Bokslut och Verksamhetsberättelse", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://view.news.eu.nasdaq.com/view?id=bb8e999164dd059108f90c64638ef95a3&lang=sv&src=listed", "language": "sv", "report_type": "annual-report", "fiscal_year": 2023, "quarter": "annual", "documents": [ { "doc_id": "nasdaq-nordic-arsredovisning-2023", "title": "Årsredovisning 2023", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/ae773646c51c9e2f2a2f1168fc7e5e9ac", "date": "2024-04-22", "period": "2023-annual", "form_type": "annual-report", "report_key": "2023:annual", "filename": "Active_Biotech_2023_Sve.pdf", "text_chars": 309681, "sha256": "dc8762605d28fa90683f0dd2f7360f7014cb8a2b80a66c487a1e0c0e45bfe00b", "url": "/company/active-biotech/documents/nasdaq-nordic-arsredovisning-2023", "absolute_url": "https://spela.port0.org/company/active-biotech/documents/nasdaq-nordic-arsredovisning-2023", "txt_url": "/company/active-biotech/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/active-biotech/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt", "parts": [ { "number": 1, "url": "/company/active-biotech/documents/nasdaq-nordic-arsredovisning-2023/part-001.html", "chars": 179795 }, { "number": 2, "url": "/company/active-biotech/documents/nasdaq-nordic-arsredovisning-2023/part-002.html", "chars": 129884 } ] } ], "alternatives": [] }, { "report_key": "2023:q4", "period_label": "2023 Q4", "date": "2024-02-08", "title": "Kvartalsrapport Q4 2023", "original_title": "Active Biotech Bokslutsrapport 2023", "category": "Bokslutskommuniké", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://view.news.eu.nasdaq.com/view?id=b604c9fbb9e1d09c0c4de418aee6a072c&lang=sv&src=listed", "language": "sv", "report_type": "year-end-report", "fiscal_year": 2023, "quarter": "q4", "documents": [ { "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2023", "title": "Kvartalsrapport Q4 2023", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/a8f42024facc84fdf446634de9530a785", "date": "2024-02-08", "period": "2023-q4", "form_type": "year-end-report", "report_key": "2023:q4", "filename": "Ab_Rapport_2023_Q4_Sve.pdf", "text_chars": 60458, "sha256": "ebce3b66d7388f46aa065db4f459da99c780abd5e9e1d65e7b797b6e9110c902", "url": "/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q4-2023", "absolute_url": "https://spela.port0.org/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q4-2023", "txt_url": "/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q4-2023/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q4-2023/fulltext.txt", "parts": [ { "number": 1, "url": "/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q4-2023/part-001.html", "chars": 60458 } ] } ], "alternatives": [] }, { "report_key": "2023:q3", "period_label": "2023 Q3", "date": "2023-11-09", "title": "Kvartalsrapport Q3 2023", "original_title": "Active Biotech Delårsrapport Q3 2023", "category": "Interimsrapport", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://view.news.eu.nasdaq.com/view?id=ba27eb7833d20e502021a62a0e3c7871a&lang=sv&src=listed", "language": "sv", "report_type": "interim-report", "fiscal_year": 2023, "quarter": "q3", "documents": [ { "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2023", "title": "Kvartalsrapport Q3 2023", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/acb03ff15ede6f7e732c107c1215c31a2", "date": "2023-11-09", "period": "2023-q3", "form_type": "interim-report", "report_key": "2023:q3", "filename": "AB_Rapport_2023_Q3_Sve.pdf", "text_chars": 57125, "sha256": "0ab6e23509f4801ef2e4592682fcfbdde699b9c747c21cb5f55148a17450a0b4", "url": "/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q3-2023", "absolute_url": "https://spela.port0.org/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q3-2023", "txt_url": "/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt", "parts": [ { "number": 1, "url": "/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q3-2023/part-001.html", "chars": 57125 } ] } ], "alternatives": [] }, { "report_key": "2023:q2", "period_label": "2023 Q2", "date": "2023-08-24", "title": "Kvartalsrapport Q2 2023", "original_title": "Active Biotech Delårsrapport Q2 2023", "category": "Halvårsrapport", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://view.news.eu.nasdaq.com/view?id=b51bf50e9e3c53c4feff148794f44717d&lang=sv&src=listed", "language": "sv", "report_type": "interim-report", "fiscal_year": 2023, "quarter": "q2", "documents": [ { "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2023", "title": "Kvartalsrapport Q2 2023", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/a7c98e6507d7d6797788f40ef09b5d08c", "date": "2023-08-24", "period": "2023-q2", "form_type": "interim-report", "report_key": "2023:q2", "filename": "AB_Rapport_2023_Q2_Sve.pdf", "text_chars": 54776, "sha256": "c636f03354ee1882c569d5de9cded35144067806557ae0a625d1ba32984715d8", "url": "/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q2-2023", "absolute_url": "https://spela.port0.org/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q2-2023", "txt_url": "/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt", "parts": [ { "number": 1, "url": "/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q2-2023/part-001.html", "chars": 54776 } ] } ], "alternatives": [] }, { "report_key": "2023:q1", "period_label": "2023 Q1", "date": "2023-05-04", "title": "Kvartalsrapport Q1 2023", "original_title": "Active Biotech Delårsrapport Q1 2023", "category": "Interimsrapport", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://view.news.eu.nasdaq.com/view?id=b41ea85cce40bfd5a91f91d5edf20a595&lang=sv&src=listed", "language": "sv", "report_type": "interim-report", "fiscal_year": 2023, "quarter": "q1", "documents": [ { "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2023", "title": "Kvartalsrapport Q1 2023", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/ad79d1d4f816db9df4983e5c20a487f00", "date": "2023-05-04", "period": "2023-q1", "form_type": "interim-report", "report_key": "2023:q1", "filename": "Ab_Rapport_2023_Q1_Sv.pdf", "text_chars": 49168, "sha256": "1df5459e6d41478ac51332604cb705bb83ffdeba18557359b0ecd6e222cccb10", "url": "/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q1-2023", "absolute_url": "https://spela.port0.org/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q1-2023", "txt_url": "/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt", "parts": [ { "number": 1, "url": "/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q1-2023/part-001.html", "chars": 49168 } ] } ], "alternatives": [] } ]